Clinical trial · Observational
A Long-term Follow-up Study of Patients Who Received VOR33
NCT05309733CI-TRIAL-00092771terminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Lack of Funding
Summary
Brief summary (as posted)
VOR33 long-term follow-up (LTFU) study
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia, Myeloid, Acute | Leukemia | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| VOR33 | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Observational Cohort 1
- description
- All patients who have received any part of or all of a VOR33 genome-edited hematopoietic stem and progenitor cell therapy product.
- interventionNames
- Genetic: VOR33
Primary outcomes (1)
- measure
- Long term safety of VOR33 in patients who participated in a VOR33 study in terms of study product-related Adverse Events/Serious Adverse Events (AEs/SAEs).
- timeFrame
- Years 1-15
- description
- Incidence of VOR33-related AEs/SAEs or deaths.
Secondary outcomes (1)
- measure
- Long term efficacy of VOR33 in patients who participated in a VOR33 study in terms of persistence of CD33-negative hematopoiesis, overall survival (OS), and monthly relapse free survival (RFS).
- timeFrame
- Years 1-15
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * A patient is included in this study if he/she: 1. Has received any part of or all of a VOR33 infusion Exclusion Criteria: * There are no exclusion criteria.
References
Publications (0)
Data not yet available
No reference posted for this study.